Novartis' Stein site will discontinue solid dose manufacturing in favour of sterile dose and cell & gene therapy production, ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad ...

Otsuka Pharmaceutical has accelerated FDA approval for Voyxact to reduce proteinuria in adults with primary IgAN at disease ...

During the UK’s Autumn Budget, Rachel Reeves has unveiled further technology investments for the UK’s National Health Service ...

The path from discovery to lifechanging therapy shouldn't be blocked by manufacturing limitations. MasterControl offers ...

UNICEF and Gavi, the Vaccine Alliance, have announced a pricing deal to expand access to the R21/Matrix-M malaria vaccine.

TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing therapies.

Developed by UCL spinout Autolus, Aucatzyl will be launched imminently across England and Wales. A UK-developed cell therapy ...

Gilead now own the rights to Sprint's preclinical oncology immunotherapy programme, which targets the novel cancer target, ...

Made Scientific and Cellergy Therapeutics have formed a partnership to advance CLG-001 mitochondrial therapy towards in-human ...

At the 2025 Veeva Commercial Summit Europe, experts touted the benefits of AI but stressed the importance of data and ...

Novartis has received approval from the US Food and Drug Administration (FDA) for the Itvisma gene replacement therapy to ...